Mostrar el registro sencillo del ítem

Postbiotics for the management of obesity, insulin resistance/type 2 diabetes and NAFLD. Beyond microbial viability

dc.rights.licenseopenen_US
dc.contributor.authorARELLANO-GARCIA, Laura Isabel
dc.contributor.authorPORTILLO, María
dc.contributor.authorMARTINEZ, J. Alfredo
hal.structure.identifierUnité de Recherche Œnologie [Villenave d'Ornon] [OENO]
dc.contributor.authorCOURTOIS, Arnaud
IDREF: 092021301
dc.contributor.authorMILTON-LASKIBAR, Iñaki
dc.date.accessioned2025-04-07T08:51:03Z
dc.date.available2025-04-07T08:51:03Z
dc.date.issued2024-12
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/206005
dc.description.abstractEnHighly prevalent comorbidities associated with metabolic syndrome, such as abdominal obesity, nonalcoholic fatty liver disease (NAFLD) and insulin-resistance/Type 2 diabetes (IR/T2D) share alterations in gut microbiota composition as a potential triggering factor. Recent studies put the attention in the potential usage of postbiotics (inactivated probiotics) on these metabolic alterations. This review summarizes the current evidence regarding the efficacy of postbiotic administration in both, preclinical and clinical studies, for the management of obesity, NAFLD and IR/T2D. Data from preclinical studies (rodents) suggest that postbiotic administration effectively prevents obesity, whereas clinical studies corroborate these benefits also in overweight/obese subjects receiving inactivated bacteria. As for NAFLD, although preclinical studies indicate that postbiotic administration improves different liver markers, no data obtained in humans have been published so far since all the studies are ongoing clinical trials. Finally, while the administration of inactivated bacteria demonstrated to be a promising approach for the management of IR/T2D in rodents, data from clinical trials indicates that in humans, this approach is more effective on IR than in T2D. In conclusion, the available scientific data indicate that postbiotic administration not only is safer, but also as effective as probiotic administration for the management of obesity associated prevalent metabolic alterations. © 2024 Taylor & Francis Group, LLC.
dc.language.isoENen_US
dc.subject.enInsulin Resistance
dc.subject.enMetabolic Syndrome
dc.subject.enNafld
dc.subject.enObesity
dc.subject.enPostbiotic
dc.subject.enProbiotic
dc.title.enPostbiotics for the management of obesity, insulin resistance/type 2 diabetes and NAFLD. Beyond microbial viability
dc.typeArticle de revueen_US
dc.identifier.doi10.1080/10408398.2024.2437143en_US
dc.subject.halSciences du Vivant [q-bio]/Biologie végétaleen_US
bordeaux.journalCritical Reviews in Food Science and Nutritionen_US
bordeaux.page1-24en_US
bordeaux.hal.laboratoriesOenologie - UMR 1366en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionBordeaux INPen_US
bordeaux.institutionINRAEen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Critical%20Reviews%20in%20Food%20Science%20and%20Nutrition&rft.date=2024-12&rft.spage=1-24&rft.epage=1-24&rft.au=ARELLANO-GARCIA,%20Laura%20Isabel&PORTILLO,%20Mar%C3%ADa&MARTINEZ,%20J.%20Alfredo&COURTOIS,%20Arnaud&MILTON-LASKIBAR,%20I%C3%B1aki&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem